mobile.zenopa.com Homepage Homepage
Employment Role Location
Business Sector Advanced
Phone 01494 818 000

View company profile
Current Jobs

Hospital Representative
Location: Kent and Sussex

CRM Manager
Location: Berkshire

Bid Support Specialist
Location: Berkshire

Senior Product Specialist
Location: Berkshire

Sales Specialist
Location: North UK

Abbott 'set to develop heart failure detection test'

Posted on 19/11/2009 in Medical Company Product News

Abbott has revealed that it plans to develop a new heart failure detection test on the Architect Immunochemistry Diagnostics Platform using a product from the firm BG Medicine.

For the purpose, it will develop and commercialise galectin-3, a novel biomarker that may be capable of detecting the progression of heart failure.

The assay will be developed for the Architect Immunochemistry Diagnostics Platform, in particular Abbott's i1000SR and i2000SR instruments.

As part of the agreement with BG Medicine, Abbott has been granted a licence to the firm's intellectual property related to galectin-3.

Michael Warmuth, senior vice-president of diagnostics products at Abbott, said: "Novel markers like galectin-3 have the potential to make important contributions to improving patient and economic outcomes as we work to better understand this deadly and costly disease."

Earlier this week, Abbott announced that a trial into its fully bioabsorbable drug eluting coronary stent produced a positive outcome.

Other news stories from 19/11/2009

Read more in the Zenopa News Archive

How this news is generated

Jo-Anne
Account Manager
for this opportunity

01494 818 012
(Mon to Fri 0830 to 1800 hours)
jo@zenopa.com

Latest News

Abbott receives FDA approval for intraocular lens

Abbott to purchase Facet Biotech

Abbott completes 4.5bn euro deal for Solvay Pharmaceuticals

Abbott's Norvir tablets approved by FDA

Abbott announces submission of ovarian test for FDA approval

home | our clients | browse news | browse jobs | links | hotel directory | Valid HTML | copyright © 2010 Zenopa Ltd | terms & conditions of use